Financial terms of the transaction have not been disclosed and are expected to have a minimal impact on revenue and earnings in the current financial year. More: Abcam acquires EdiGene’s cell lines and lysates portfolio Source: News
read moreCAD is the most common type of heart disease in the United States, as up to one half of middle aged men and one third of middle aged women in the US are at risk of developing CAD during their
read moreDecisions include restricting who can prescribe these medicines, making warnings on the packaging more prominent and providing educational materials. More: PRAC recommends new measures for methotrexate Source: News
read moreNovartis has been busy doing M&A to focus on higher-margin, innovative medicines under CEO Vas Narasimhan. Toward that goal, the Swiss drugmaker has taken another step and offloaded three endocrine drugs to Recordati. More: Novartis offloads lagging endocrine drugs to Recordati
read moreThe FDA’s March rejection of Sanofi and Lexicon Pharmaceuticals’ Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes. The agency shot down AstraZeneca’s Farxiga, which could have used the sales boost in
read moreIndoco Remedies is not just getting the once over by the FDA but the twice-over as inspectors work through its plants and citations rain down. More: Indoco caught in maelstrom of FDA concerns as plant hit with warning letter Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals